timothy sykes logo

Stock News

TNDM Stock’s Recent Surge: Time to Ride the Wave or Watch Closely?

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
TNDM Stock’s Recent Surge: Time to Ride the Wave or Watch Closely? Thumbnail

Tandem Diabetes Care Inc.’s stock movement on Tuesday can be largely attributed to news of its enhanced insulin delivery system significantly improving patients’ blood sugar management. On Tuesday, Tandem Diabetes Care Inc.’s stocks have been trading up by 5.89 percent.

Key Developments Driving TNDM’s Movement

  • Morgan Stanley’s recent upgrade of Tandem Diabetes Care to an Overweight rating with a price target of $45 indicates significant undervaluation despite strong performance.

Candlestick Chart

Live Update At 17:20:43 EST: On Tuesday, December 10, 2024 Tandem Diabetes Care Inc. stock [NASDAQ: TNDM] is trending up by 5.89%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

  • Tandem Diabetes Care set to gain visibility and investor interest with upcoming presentations at high-profile investor conferences, including the 36th Annual Piper Sandler Healthcare Conference.

  • Analysts highlight Tandem’s successful MOBI rollout as a key factor in the company’s promising trajectory, potentially boosting its growth prospects.

  • Upgraded price target of $53.30 by analysts demonstrates confidence in Tandem’s strategic direction and market position.

Overview of Tandem Diabetes Care Inc.’s Earnings and Financial Health

As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.” In the world of trading, having a strategic plan is crucial. It’s important to analyze market trends and make informed decisions, but equally important is understanding risk management and preserving your initial capital. Being overly focused on winning every trade can lead to unnecessary risks and potential losses. Instead, focusing on consistency, learning from each trade, and progression in skills will ultimately lead to long-term success.

Tandem Diabetes has recently been climbing the investor charts with performance data that paints a compelling story. Let’s delve into the numbers to see why it’s catching so much attention.

First, recent earnings reports reveal a mixed bag. Tandem recorded revenue of approximately $243.97M for Q3 2024, a solid number that speaks to growth in product demand. But digging deeper, the net income stands at a loss of approximately $23.25M, showing that while sales are high, profitability remains a challenge. The overall loss is somewhat expected in an industry with high research and development costs, and Tandem is no exception with its ongoing investment in innovation.

The company’s financial ratios tell an interesting tale. Its gross margin is notably high at 49.8%, reflecting the company’s efficient production costs relative to its sales. Yet, profitability metrics like the EBIT margin of -14.1% indicate there is more work to be done to translate top-line gains into bottom-line success.

More Breaking News

Liquidity ratios—current ratio of 2.9 and quick ratio of 2.2—suggest Tandem has a strong capacity to cover short-term liabilities with current assets, providing some cushion for maneuvering through lean periods. However, the leverage ratio, high at 4, raises questions about the company’s debt levels and how it may tackle these moving forward.

Story Behind the Numbers: What It All Means

The financial narrative doesn’t stop at ratios and earnings. Tandem’s stock fluctuated with notable daily highs and some breathtaking lows. For instance, in recent trading, the stock opened at $31.93, climaxed at $34, dipped to $31.71, and closed strongly at $33.81. This kind of rollercoaster reflects underlying volatility, often influenced by broader market sentiments and investor reactions to news.

Now, enhancing its appeal to investors, Tandem is not sitting idle. Participation in industry conferences provides a platform to showcase advancements like the MOBI rollout. This innovative technology could indeed reshape diabetes care, placing Tandem in a competitive spot with its peers. It’s a strategic move that’s likely to generate buzz and bolster market trust.

The aforementioned analyst upgrades from reputable firms like Morgan Stanley spice things up. Their confidence in the stock, predicated on perceived undervaluation, carries weight and implies future potential. It sends a message that, while financial performance is not yet perfect, long-term prospects might be brighter.

Conclusion: Assessing the Path Ahead for Tandem Investors

In conclusion, assessing Tandem Diabetes Care’s growth prospects requires a dual focus. Traders must look at both current challenges and upcoming opportunities. The market’s faith in Tandem, seen in rating upgrades and conference spotlights, could inspire further upward momentum if executed correctly. As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” For those considering riding the Tandem wave, staying informed on company updates and broader market trends will be key. But remember, trading in stocks with a volatile history requires caution and a readiness to adapt to new information.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Our traders will never trade any stock until they see a setup they like. Their strategy is to capture short-term momentum while avoiding undue risk exposure to a stock’s long-term volatility. This method is especially useful when trading penny stocks or other high-risk equities, where rapid gains can be made by understanding stock patterns, manipulation, and media hype. Whether you are an active day trader looking for key indicators on a stock’s next move, or an investor doing due diligence before entering a position, Timothy Sykes News is designed to help you make informed trading decisions.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade, the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

Ready to embark on your financial adventure? Click the links and let the journey unfold.

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”